Top Suppliers:I want be here

2363169-01-9

2363169-01-9 structure
2363169-01-9 structure
  • Name: c-Kit inhibitor 3
  • Chemical Name: c-Kit-IN-3
  • CAS Number: 2363169-01-9
  • Molecular Formula: C26H20ClF3N2O4
  • Molecular Weight: 516.90
  • Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK c-Kit
  • Create Date: 2019-12-08 16:59:19
  • Modify Date: 2024-01-20 20:59:22
  • c-Kit-IN-3 (Compound 18) is a potent and selective c-KIT kinase inhibitor with an IC50s of 4 nM, 8 nM for c-KIT wt and c-KIT T670I, respectively. c-Kit-IN-3 displays great potencies against most of the gain-offunction mutations in the juxtamembrane domain, drugresistant mutations in the ATP binding pocket, and activation loops[1].

Name c-Kit-IN-3
Description c-Kit-IN-3 (Compound 18) is a potent and selective c-KIT kinase inhibitor with an IC50s of 4 nM, 8 nM for c-KIT wt and c-KIT T670I, respectively. c-Kit-IN-3 displays great potencies against most of the gain-offunction mutations in the juxtamembrane domain, drugresistant mutations in the ATP binding pocket, and activation loops[1].
Related Catalog
Target

IC50: 4 nM (c-KIT kinase)[1]

In Vitro c-Kit-IN-3 (Compound 18; 0.1-10 μM; 6 days; primary GIST patient cells) exhibits dose-dependent antiproliferative effects[1]. c-Kit-IN-3 (0.01-1 μM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment induces dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3)[1]. c-Kit-IN-3 (0.01-1 μM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment arrests the cell cycle into the G0/G1 phase in all of these three cell lines[1]. c-Kit-IN-3 (0-1 μM; 24 hours) blocks the autophosphorylation of c-KIT pY703, pY719, and pY823 in GIST-T1, GIST-T1-T670I, and GIST-5R, respectively, cells at a concentration of 30 nM and inhibits the downstream signaling mediators pAKT (T308/S473), pS6 (S235/236), and pERK (T202/204)[1].  c-Kit-IN-3 potently inhibits the activity of CSF1R (IC50: 18 nM), PDGFRα (IC50: 25 nM), RET (IC50: 34 nM), and it relatively less potently inhibits DDR1 (IC50: 135 nM), FLT4 (IC50: 121 nM), and PDGFRβ (IC50: 97 nM)[1]. c-Kit-IN-3 (0.006 μM-1.37 μM) potently inhibits the growth of c-KIT-dependent GIST cancer cells, such as GIST-T1 (IC50: 0.006 μM); GIST-882 (IC50: 0.013 μM); GIST-T1-T670I (IC50: 0.011 μM); GIST-5R (IC50: 0.073 μM); GIST-48B (IC50: 1.37 μM), respectively[1]. Cell Proliferation Assay[1] Cell Line: Primary GIST patient cells Concentration: 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM Incubation Time: 6 days Result: Inhibition of the proliferation of primary GIST patient cells. Cell Cycle Analysis[1] Cell Line: GIST-T1, GIST-T1-T670I, and GIST-5R cells Concentration: 0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM Incubation Time: 24 hours Result: Arrested the cell cycle into the G0/G1 phase in all of these three cell lines. Apoptosis Analysis[1] Cell Line: GIST-T1, GIST-T1-T670I, and GIST-5R cells Concentration: 0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM Incubation Time: 24 hours Result: Induced dose-dependent cells apoptotic death. Western Blot Analysis[1] Cell Line: GIST-T1, GIST-T1-T670I, and GIST-5R cells Concentration: 0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM Incubation Time: 24 hours Result: Decreased the autophosphorylation of c-KIT pY703, pY719, and pY823 in GIST-T1, GIST-T1-T670I, and GIST-5R cells, respectively.
In Vivo c-Kit-IN-3 (Compound 18; 40-100 mg/kg; oral gavage; daily; for 11 days; for 4 weeks; female BALB/C-nu mice) treatment dose dependently inhibits the BaF3-tel-c-KIT-T670I tumor progression and exhibited almost 100% TGI (tumor growth inhibition) at a dosage of 100 mg/kg/day. And do not affect the animal weights[1]. Animal Model: Female BALB/C-nu mice bearing established BaF3-tel-c-KIT-T670I tumor xenografts[1] Dosage: 40 mg/kg, 100 mg/kg Administration: Oral gavage; daily; for 11 days Result: Dose dependently inhibited the BaF3-tel-c-KIT-T670I tumor progression and exhibited almost 100% TGI (tumor growth inhibition) at a dosage of 100 mg/kg/day.
References

[1]. Wu Y, et al. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. J Med Chem. 2019 Jul 11;62(13):6083-6101.

Molecular Formula C26H20ClF3N2O4
Molecular Weight 516.90
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.